Related Experiment Video
Updated: Aug 29, 2026

Neutron Radiography and Computed Tomography of Biological Systems at the Oak Ridge National Laboratory's High Flux Isotope Reactor
Published on: May 7, 2021
Abstract:
CHF 3381 is an NMDA antagonist and monoamine oxidase inhibitor under development with Chiesi for the treatment of neuropathic pain. Preclinical studies show that the agent acts as a reversible and competitive inhibitor of human monoamine oxidases A and B. At the 1st Annual BioPartnering North America (BPN-2003) it was stated that CHF 3381 is being evaluated for the treatment of neuropathic pain. Preliminary data also suggested that CHF 3381 may have neuroprotective activity. In June 2003, Chiesi announced the completion of a phase I trial in France, and is proceeding with a proof-of-concept study in Denmark. CHF 3381 is covered by European patent application EP 951465 (expires on 15 July 2017), and US patent No. 6,114,391 (issued on 5 September 2000). Other patents are granted or pending in 20 countries. Chiesi also has rights to the European patent application for use of glycinamide derivatives (including CHF 3381) in the treatment of chronic pain.
Related Concept Videos
Dimensional Analysis
Conversion Factors and Dimensional Analysis
The unit...
Titration Calculations: Weak Acid - Strong Base
For the titration of 25.00 mL of 0.100 M CH3CO2H with 0.100 M NaOH, the reaction can be represented as:
Free Energy and Equilibrium
Recall that Q is the numerical value of the mass action expression...
Standard Entropy Change for a Reaction
Balancing Redox Equations
Measurement: Derived Units
